Peer reviews & research outputs

*

All papers published as a result of the work done in the Trials@Home will be published here.

Which Benefits Can Justify Risks in Research?

First published: 5 January 2024

Authors: Tessa I. van Rijssel, Ghislaine J. M. W. van Thiel, Helga Gardarsdottir, Johannes J. M. van Delden, on behalf of the Trials@Home consortium

Opportunities and challenges for decentralized clinical trial approaches: European health technology assessment perspective

First published: 1 December 2023

Authors: Amos J. de Jong, MSc, Nadi Shahid, BSc, Mira G.P. Zuidgeest, PhD, Yared Santa-Ana-Tellez, PhD, Milou Hogervorst, PharmD, Wim Goettsch, PhD, Hamidou Traore, PhD, Anthonius de Boer, PhD, Helga Gardarsdottir, PhD, on behalf of theTrials@Home Consortium

Direct-to-Participant Investigational Medicinal Product Supply in Clinical Trials in Europe – Exploring the Experiences of Sponsors, Site Staff, and Couriers

First published: 12 July 2023

Decentralised, patient-centric, site-less, virtual, and digital clinical trials? From confusion to consensus

First published: 6 February 2023

Which decentralised trial activities are reported in clinical trial protocols of drug trials initiated in 2019–2020? A cross-sectional study in ClinicalTrials.gov

First published: 29 August 2022

A secondary qualitative analysis of stakeholder views about participant recruitment, retention, and adherence in decentralised clinical trials (DCTs)

First published: 30 July 2022

Ethics review of decentralized clinical trials (DCTs): Results of a mock ethics review

First published: 20 July 2022

Opportunities and Challenges for Decentralized Clinical Trials: European Regulators’ Perspective

First published: 30 April 2022

A Systematic Review of Methods used to Conduct Decentralised Clinical Trials

First published: 27 December 2021

Learning from remote decentralised clinical trial experiences: A qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders

First published: 13 July 2021

COVID‐19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European Union

First published: 05 March 2021